[Comparison of the efficacy of gadobutrol and multihance in contrast-enhanced MRI for diagnosis of brain metastasis in lung cancer].
To investigate the diagnostic efficacy of gadobutrol for assessing brain metastases in lung cancer patients in comparison with multihance. 21 patients with lung cancer suspected of brain metastasis were enrolled in this study. All patients underwent twice MRI scans on a 3.0T MRI scanner (Siemens MAGENETOM Trio) with 8-channel head coil, first with 0.5 mol/L multihance and then with 1.0 mol/L gadobutrol as contrast agent. The dosage of contrast agent was set at 0.1 mmol/kg body mass. The interval between the two scans was 24-72 hours. The detection and delineation of lesions were evaluated visually. The signal-to-noise ratios (SNR), contrast-to-noise ratios (CNR) of lesion to normal brain white matter and the percentage of lesion enhancement were calculated and compared between the two scans by 2 experienced neuroradiologists. One patient was excluded because he received radiation therapy between the two scans. 15 patients were found to have brain metastases with a total of 35 lesions. There were no statistical differences between the two scans in SNR, CNR and percentage enhancement for both normal brain and lesions (t = 0.545, P = 0.592; t = 1.143, P = 2.267; t = 0.592, P = 0.557; t = 0.473, P = 0.639). Half-dose gadobutrol (1.0 mol/L) can achieve the same enhancement effects compared with full-dose multihance (0.5 mol/L).